2025 · 2nd Quarter (Apr 1 - June 30)

REGENERON PHARMACEUTICALS, INC.

Filed by THE WASHINGTON TAX & PUBLIC POLICY GROUP.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 11, 2025
Income: $30,000.00
Expenses: Not reported
Registrant: THE WASHINGTON TAX & PUBLIC POLICY GROUP
Client: REGENERON PHARMACEUTICALS, INC.
Filing UUID: 4f45106c-43fb-42a1-bb7f-fc3b271318b5
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

TAX · Taxation/Internal Revenue Code

Issues related to corporate and international taxation. Issues related to OECD Pillar 2 negotiations and agreements on the taxation of global income. Issues related to IRC sections 11, 951A, 250, 162(m), and 174. (H.R. 1990, S. 1649, H.R. 1 - Sections - 70321, 70322, 70323, 70302, 70604)

Literal federal measure citations: H.R. 1990, S. 1649, H.R. 1

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.